← All trials
NCT06701669
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 6, 2025
- Primary completion
- Nov 26, 2027
- Completion date
- Feb 8, 2028
- First posted
- Nov 22, 2024
- Last posted
- Nov 27, 2024
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PPDLead sponsor
- GenentechCollaborator
- Department of Health and Human ServicesCollaborator
- InflaRx GmbHCollaborator
- Edesa Biotech Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.